Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved treatment for the myotonia symptoms ...

Mumbai: Global pharma major Lupin Limited and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved treatment for the myotonia symptoms in adults with non-dystrophic myotonic disorders Mumbai, Zug, January ...

Lupin and Avas launch NaMuscla in Italy to treat myotonia in adults with NDM disorders: Our Bureau, Mumbai Tuesday, January 28, 2025, 16:45 Hrs [IST] Global pharma major Lupin Lim ...

Experts at the e4m India Brand Conclave 2025 emphasised brand identity, storytelling, and strategic platform selection for ...

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who ...

Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...

Lupin Ltd share price was down by -0.79% from ... Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here ...

Global pharma major Lupin Limited on Thursday announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug ...